Clinical trial NCT03489369: Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Official title: A Phase 1, Open-Label, Multicenter Trial Investigating the Safety, Tolerability, and Preliminary Antineoplastic Activity of Sym022 (Anti-LAG-3) in Patients With Advanced Solid Tumor Malignancies or Lymphomas
Study type: INTERVENTIONAL
Overall status: COMPLETED
Phase: PHASE1
Conditions: Metastatic Cancer
Solid Tumor
Lymphoma
Keywords: Locally advanced/unresectable
Metastatic solid tumor
Lymphoma
Anti-LAG-3
LAG-3
LAG3
Lead sponsor: Symphogen A/S
Sponsor class: INDUSTRY
First posted: 2018-04-05
Enrollment: 15
Sex: ALL
Minimum age (years): 18
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Primary purpose: TREATMENT

Brief summary: This is the first study to test Sym022 in humans. The primary purpose of this study is to see if Sym022 is safe and tolerable for patients with locally advanced/unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available.

Detailed description: This study will evaluate the preliminary safety, tolerability, and dose-limiting toxicities (DLTs) of Sym022, an anti-lymphocyte activation gene 3 (anti-LAG-3) monoclonal antibody (mAb). The goal is to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of sequential escalating doses of Sym022 when administered once every 2 weeks (Q2W) by intravenous (IV) infusion to patient cohorts with locally advanced/ unresectable or metastatic solid tumor malignancies or lymphomas that are refractory to available therapy or for which no standard therapy is available. If an MTD is not identified, a maximum administered dose (MAD) will be determined. Sym022 will be given to patients in escalating dose cohorts; each patient will be given one fixed dose level.

Eligibility criteria: Inclusion Criteria:

* Male or female patients, ≥ 18 years of age at the time of obtaining informed consent.
* Documented (histologically- or cytologically-proven) solid tumor malignancy that is locally advanced or metastatic; patients with documented lymphomas.
* Malignancy (solid tumor or lymphoma) that is currently not amenable to surgical intervention due to either medical contraindications or nonresectability of the tumor.
* Refractory to or intolerant of existing therapy(ies) known to provide clinical benefit.
* Measurable or non-measurable disease according to RECIST v1.1 or RECIL 2017.
* Eastern Cooperative Oncology Group (ECOG) performance status (PS) of 0 or 1.
* Not of childbearing potential or who agree to use a highly effective method of contraception during the study beginning within 2 weeks prior to the first dose and continuing until 6 months after the last dose of study drug.

Exclusion Criteria:

* Women who are pregnant or lactating, or intending to become pregnant before, during, or within 6 months after the last dose of study drug. Women of childbearing potential (WOCBP) and fertile men with WOCBP partner(s), not using and not willing to use a highly effective method of contraception.
* Known, untreated central nervous system (CNS) or leptomeningeal metastases, or spinal cord compression, patients with any of the above not controlled by prior surgery or radiotherapy, or patients with symptoms suggesting CNS involvement for which treatment is required.
* Hematologic malignancies other than lymphomas.
* Active thrombosis, or a history of deep vein thrombosis (DVT) or pulmonary embolism (PE) within 4 weeks prior to Cycle 1/Day 1 (C1/D1) unless adequately treated and considered stable
* Active uncontrolled bleeding or a known bleeding diathesis
* Clinically significant cardiovascular disease or condition
* Significant pulmonary disease or condition
* Current or recent (within 6 months) significant gastrointestinal (GI) disease or condition.
* An active, known, or suspected autoimmune disease, or a documented history of autoimmune disease or syndrome, requiring systemic steroids or other immunosuppressive medications.
* History of organ transplantation (e.g. stem cell or solid organ transplant)
* History of significant toxicities associated with previous administration of immune checkpoint inhibitors that necessitated permanent discontinuation of that therapy
* Patients with unresolved \> Grade 1 toxicity associated with any prior antineoplastic therapy, with exceptions.
* Inadequate recovery from any prior surgical procedure, or having undergone any major surgical procedure within 4 weeks prior to C1/D1.
* Known history of human immunodeficiency virus (HIV) or known active infection with hepatitis B virus (HBV) or hepatitis C virus (HCV).
* Other Inhibitors of LAG-3
* Any antineoplastic agent for the primary malignancy (standard or investigational) without delayed toxicity within 4 weeks or 5 plasma half-lives, whichever is shortest, prior to first administration of study drug and during study
* Any other investigational treatments within 4 weeks prior to and during study
* Radiotherapy for target lesions within 4 weeks prior to first administration of study drug unless PD has been documented in the lesion following treatment, and during study.
* Radiotherapy for non-target lesions within 1 week prior to first administration of study drug
* Immunosuppressive or systemic hormonal therapy
* Prophylactic use of hematopoietic growth factors within 1 week prior to first administration of study drug and during Cycle 1 of study

Primary outcomes:
measure: Assessment of Treatment Related Adverse Events (AEs).
timeFrame: 19 months
Secondary outcomes:
measure: Evaluation of the Immunogenicity of Sym022.
timeFrame: 19 months
measure: Evaluation of Objective Response (OR) or Stable Disease (SD).
timeFrame: 13 months
measure: Time to Progression (TTP) of Disease.
timeFrame: 13 months
measure: Area Under the Concentration-time Curve in a Dosing Interval (AUC).
timeFrame: 19 months
measure: Maximum Concentration (Cmax)
timeFrame: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
measure: Time to Reach Maximum Concentration (Tmax)
timeFrame: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
measure: Trough Concentration (Ctrough)
timeFrame: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
measure: Terminal Elimination Half-life (T½)
timeFrame: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
measure: Clearance (CL)
timeFrame: 0, 2, 4, 8, 24, 48, 168 hours and 336 hours as administered Q2W (every second week)
Other outcomes:
Locations:
city: Grand Rapids
country: United States
facility: South Texas Accelerated Research Therapeutics (START) Midwest
state: Michigan
city: Houston
country: United States
facility: The University of Texas MD Anderson Cancer Center
state: Texas
city: Toronto
country: Canada
facility: Princess Margaret Cancer Centre
state: Ontario
Study officials:
affiliation: Princess Margaret Cancer Centre
name: Lillian Siu, MD, FRCPC
role: PRINCIPAL_INVESTIGATOR
References: